BioSenic S.A.

Transparency notifications received from François Rieger

 PRESS RELEASE – REGULATED INFORMATION

Article 14 of the Law of 2 May 2007 on disclosure of major holdings

Mont-Saint-Guibert, Belgium, January 15, 2024, 7am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received transparency notifications from François Rieger that can be consulted on the website of BioSenic, under the heading “Major shareholders & transparency notices”.

The transparency notification indicates that the shareholdings held by François Rieger have crossed below the threshold of 15% as a result of a share lending on 10 January 2024. 

The notification received from François Rieger dated 12 January 2024 contains the following information:

• Reason for the notification:
  • Passive crossing of a threshold
• Notification by: A person that notifies alone
• Person subject to the notification requirement: François Rieger
• Transferor of voting rights: François Rieger
• Transaction date: 10 January 2024
• Threshold that is crossed: 15%
• Denominator: 163 181 474
• Notified details:
  
  

Voting rights	Previous notification	After the transaction
Holders of voting rights	# of voting rights	# of voting rights	% of voting rights
François Rieger	26 589 361	18 589 361	11.39%
Total voting rights		18 589 361	11.39%

About BioSenic

BioSenic is a biotech company specializing in the development of clinical assets issued from: (i) the arsenic trioxide (ATO) platform (with key target indications including Graft-versus-Host Disease (GvHD), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) and (ii), the development of innovative products to meet unmet needs in immune and autoimmune diseases. Following a reverse merger in October 2022, BioSenic combined its strategic positioning and key strengths to develop, separately and in combination, an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO) with its innovative cell therapy platform and strong IP for tissue repair protection.